The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Hum

详细信息    查看全文

• 作者：Zahra Hanaizi^a ; ^{zahra.hanaizi@ema.europa.eu} ; Barbara van Zwieten-Boot^b ; Gonzalo Calvo^c ; Arantxa Sancho Lopez^c ; Maaike van Dartel^b ; Jorge Camarero^c ; Eric Abadie^d ; Francesco Pignatti^a
• 关键词：Ipilimumab ; Melanoma ; EMA ; European Medicines Agency
• 刊名：European Journal of Cancer
• 出版年：2012
• 出版时间：January 2012
• 年：2012
• 卷：48
• 期：2
• 页码：237-242
• 全文大小：347 K

文摘

On 13 July 2011 the European Commission issued a marketing authorisation valid throughout the European Union (EU) for ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy.

Ipilimumab is a monoclonal antibody that specifically blocks the inhibitory signal of cytotoxic T lymphocyte antigen 4 (CTLA-4), resulting in T cell activation, proliferation and lymphocyte infiltration into tumours, leading to tumour cell death. The recommended induction regimen of ipilimumab is 3 mg/kg administered intravenously over a 90 min period every 3 weeks for a total of four doses.

In a phase 3 trial in patients with advanced melanoma, median overall survival for ipilimumab was 10 months versus 6 months for gp100, an experimental melanoma vaccine (Hazard ratio (HR) 0.66; 95 % confidence interval (CI): 0.51, 0.87; p = 0.0026).

Ipilimumab was most commonly associated with adverse reactions resulting from increased or excessive immune activity. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of ipilimumab. The most common side-effects (affecting more than 10 % of patients) were diarrhoea, rash, pruritus, fatigue, nausea, vomiting, decreased appetite and abdominal pain. The objective of this paper is to summarise the scientific review of the application leading to approval in the EU. The detailed scientific assessment report and product information, including the summary of product characteristics (SmPC), are available on the European Medicines Agency (EMA) website ().